NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
Clinical Trials
9 trialsNCT02580552 2020-11-23
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
miRagen Therapeutics, Inc.
Phase 1 Completed
NCT01169298 2019-11-08
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
Celgene
Phase 1 Completed
NCT03226119 2018-09-13
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
MP Biomedicals, LLC
Phase 4 Completed
NCT01724177 2018-05-29
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Celgene
Phase 2 Completed
NCT03146013 2017-06-12
Dual Algorithm Post Market Clinical Study
MP Biomedicals, LLC
Completed
NCT01173887 2017-03-30
Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00920790 2017-03-29
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00355472 2012-10-18
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
Kyowa Kirin Co., Ltd.
Phase 1 Completed